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Abstract 
Human recombinant a-parvalbumin (PVwt) and nine mutant proteins, containing inactivating substitutions at positions essential for 
Ca 2+ binding in the CD Ca2+-binding site (PVE62V, PVDslA, PVDs1A,62V), the EF site (PVE101 v, PVD90A, PVDgoA,ElO w) or in both 
(PVE62V,ElOlV, PVDs1A,D90A, PVD51A,E62V,Dg0A.EI01V), were expressed and purified. Flow dialysis revealed that PVwt binds 2 Ca 2÷ with 
equal K~a, of 2.3 × 107 M -!  and that Mg 2+ competes with a K~lg.compet. of 4.9 × 10 3 M -1. The three mutants with an inactivated CD 
site bind 1 Ca 2÷ with K~a, of 2.0 to 2.3 × 107 M - I  and K~lg.compet. of 3.4 to 4.6 × 10 3 M - I ,  i.e. very similar to those of PVwt. The 
mutants with an inactivated EF site bind 1 Ca 2+ with K~a values of 7.9 × 10 6, 4.5 X 10 6 and 3.6 × 10 6 M- 1 for PVD91A, PVE~02 v and 
PVE101V,D91A, respectively. The K~g.compet. values of these mutants are about 4-times lower than in PVwt. The three mutants with both 
2+ 2+ sites inactivated bind neither Ca nor Mg . After excitation at 259 nm, human PV, which contains neither Tyr nor Trp, shows maximal 
fluorescence emission at 283 nm. Binding of either Ca 2+ or Mg 2+ to PVwt or to mutants with an inactivated EF site lead to a 1.8-fold 
decrease in fluorescence intensity, whereas the mutants with an inactivated CD show only a very slight decrease upon binding of Ca 2÷ or 
Mg 2+. Specific antibodies against human a-parvalbumin were raised in rabbits. Their reactivity was tested against he mutant proteins, 
and their potential value for location and functional studies was investigated. 
Keywords: Calcium binding protein; a-Parvalbumin; EF-hand; Mutagenesis; Antibody; (Human) 
1. Introduction 
Parvalbumins (PV) belong to the large family of Ca 2÷- 
binding proteins characterized by the EF-hand structural 
motif [1,2]. In vertebrates, two isoforms (or and 13) are 
expressed, differing by several biochemical properties and 
their chromosomal location [3,4]. Furthermore, species dif- 
fer in their number of isoforms, tissue expression, and 
cellular localization. For example, o~-PV is highly ex- 
pressed in the fast-twitch skeletal muscles of mice and rats 
Abbreviations: PV, o~-parvalbumin; PAGE, polyacrylamide gel elec- 
trophoresis; ESI, electrospray ionisation; MS, mass spectrometry; PCR, 
polymerase chain reaction; IPTG, isopropyl 13-D-thiogalactopyranoside; 
PMSF, phenylmethylsulfonyl fluoride. 
* Corresponding author. Fax: +41 1 2667169; e-mail: 
heizmannc@wawona.vmsmail.ethz.ch. 
[5] acting there as a muscle relaxation factor [1,6,7]. In the 
corresponding muscles of man, however, u-PV is ex- 
pressed at a very low level [8]. Similarly, 13-PV (also 
named oncomodulin) is highly expressed in rat tumors, but 
not in human neoplasms [9]. In man, 13-PV is found in the 
cytotrophoblasts of the placenta [10]. This demonstrates 
that previous results on or- and 13-PVs from various animal 
species are difficult to transfer to functional and clinical 
studies in humans. 
One of our research goals is to study the function of 
a-PV in neurons of the central nervous ystem of man and 
try to explain its altered expression and cellular distribu- 
tion in human neurodegenerative disorders [11]. Those 
studies have been inconsistent in the past because of a lack 
of specific human probes (cDNAs, proteins and antibodies) 
for cell transfection experiments and localization studies. 
As a first approach, we expressed and purified human 
recombinant ot-PV and nine mutants and studied the con- 
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sequences on the properties of site-inactivation in human 
recombinant o~-PV. Usually, inactivation of an EF-hand 
site is carried out by mutating the critical residue Asp in 
the +X position and/or Glu in -Z .  Here, nine mutants 
with different combinations were constructed and the ef- 
fect of the mode of inactivation on Ca 2 +-binding properties 
was examined. In addition, we raised for the first time 
antibodies against human ct-PV and tested its reactivity 
against he mutant proteins for future applications in func- 
tional studies. 
2. Materials and methods 
was added for another 4-5 h. Bacteria were harvested and 
resuspended in 10 mM Tris (pH 8.5) 0.1 mM PMSF. After 
sonication the cell lysate was frozen at - 20°C. The thawed 
lysate was heated to 80°C for 10 min, cooled on ice, and 
centrifuged at 27 000 × g for 30 min at 4°C. The cleared 
lysate was adjusted to pH 8.5 and applied to a 1.6 × 6 cm 
Q Sepharose Fast Flow column (Pharmacia, Uppsala, Swe- 
den) equilibrated in the resuspension buffer. After washing 
the column by 20 bed volumes of 10 mM Tris (pH 8.5), 
the protein was eluted by addition of 50 mM NaC1 to the 
washing buffer. Homogenous protein-containing fractions 
were identified by SDS-PAGE [14] and Coomassie bril- 
liant blue staining. 
2.1. Mutations of human parvalbumin cDNA 2.4. Gel electrophoresis and mass spectrometry 
Site-directed mutagenesis was carded out in order to 
modify the human PV cDNA [8] (GenBank/EMBL acces- 
sion number X63070). One or both of the functional 
Ca2+-binding sites (CD- or EF-domain) were inactivated 
by replacing either the first or last, or both, amino acids, 
Asp and Glu, in the Ca2÷-binding loops by the two 
non-polar amino acids, Ala and Val, respectively. The 
resulting mutant proteins are PVE101 v, PVD90A , and 
PVD90A.E101V (collectively called PV_EF), PVE62V, PVDs1A, 
and PVDsIA,62V (collectively called PV  CD), PVE62V,EI01V, 
PVD51A,D90A, and PVD51A.E62V.O90A,E 10IV (collectively called 
PV_cD/_EF). All site directed mutagenesis experiments 
were performed as described [12] and confirmed by DNA 
sequence analysis [13]. The primers used to introduce 
mutations in the Ca2+-binding sites were: PVD51A 5'-TT- 
TTGTCCTTGGCCAGCATGT-3', PVE62V 5'-TGAATC- 
CCAGCACATCCTCCT-3', PVD90A 5'-CCCATCTTTG- 
GCTCCAGCAGC-3', and PVE101V 5'-AGTGGAGAA- 
TACGTCAACCCC-3'. 
2.2. Construction of expression vectors 
SDS-PAGE (15%) under reducing conditions was per- 
formed as described [8]. IEF was carded out under dena- 
turing conditions [15]. The isoelectric point of the proteins 
was calculated by the Wisconsin Software Package, Ver- 
sion 8 (Genetics Computer Group, Madison, WI, USA). 
ESI-mass spectrometry and amino acid analysis of puri- 
fied proteins was performed as described [16]. 
2.5. Protein and metal ion determination and metal re- 
moval 
The proteins were precipitated with 3% trichloroacetic 
acid and then passed through a 40 × 1 cm Sephadex G-25 
column equilibrated in Ca2+-free 50 mM Tris-HC1 (pH 
7.5), 150 mM KCI (buffer A). Total Ca 2÷ and Mg 2+ 
concentrations were determined with a Perkin-Elmer in- 
strument 2380 atomic absorption spectrophotometer as pre- 
viously described [17,18]. The protein concentration was 
determined from the ultraviolet absorption spectrum using 
a molar extinction coefficient at 259 nm of 2500 M-1 
cm- 1. 
The wild-type and nine mutant hPV fragments were 
cloned into the bacterial expression vector pGEMEX-2 
(Promega, Madison, WI) where the NdeI cleavage site at 
position 3259 has been deleted. The PV mutant open 
reading frames were amplified by PCR using 5' and 3' 
flanking primers PVNDE 5'-AGTCATATGTCGAT- 
GACAGACTTG-3' and PVHIND 5'-CTGAAAGCTT- 
CAGAGAGGTGGAAGACCAGG-3' in order to clone in 
the NdeI and HindlII cleavage site of pGEMEX-2. The 
constructs were confirmed by DNA sequencing. 
2.6. Cation binding studies 
Ca 2 + binding was measured at 25°C by the flow dialy- 
sis method on 30-50 IxM protein solutions, containing 
various concentrations of MgC12. Treatment of the raw 
data was as described by Cox et al. [19]; refined analysis 
of the Mg 2÷ effects was done as described by Pauls et al. 
[17]. We estimate that the accuracy on the binding con- 
stants obtained from flow dialysis experiments i around 
80%. 
2.3. Expression and purification of mutant proteins 2.7. Spectrofluorimetry 
Bacteria from E. coli strain BL21(DE3)pLysE carrying 
the expression plasmid were grown in Luria-Bertani 
medium containing 100 mg/ l  ampicillin, 10 mg/ l  chlor- 
amphenicol, and 2 mM MgCl 2. The culture was grown to 
an optical density of 0.4 at 600 nm, then 0.5 mM IPTG 
Emission fluorescence spectra were taken with a 
Perkin-Elmer LS-5B spectrofluorimeter on metal-free solu- 
tions of 50 lxM mutant PVs in buffer A at room tempera- 
ture with excitation wavelength at 259 nm and slits of 5 
nm. 2 mM MgCl 2 and 1 mM CaCI 2 were added subse- 
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Fig. 1. Purification of the recombinant cx-PVwt and of the nine mutants. (A) SDS-PAGE of recombinant heVwt with 100 I~1 of bacterial culture before (lane 
1) and after (lane 2) induction with IPTG. (B) Electrophoretic mobility of PVwt and nine mutants in the presence of Ca 2+. 2 I-~g of each protein was 
applied. PVwt (lane 1); PVEI01 v (lane 2); PVD90A (lane 3); PVE62V (lane 4); PVnsIA (lane 5); PVD90A.EI0tV (lane 6); PVE62V.EI01V (lane 7); PVD51A,D90 A 
(lane 8); PVD51A,E62 v (lane 9); PVD51A,E62V,D90A,EIOIV (lane 10). Proteins were visualized with Coomassie brilliant blue. 
quently to obtain the Mg 2÷ and Ca 2+ form, respectively. 
Alternatively, guanidine hydrochloride up to 4 M was 
added to obtain the fully denatured form. 
2.8. Antibodies and Western blot analysis 
Polyclonal antisera against human recombinant ct-PV 
were raised in rabbits. Animals were immunized with 1 mg 
of protein in Freund's complete adjuvant and then boosted 
five times at 3 week intervals with 0.1 mg of protein in 
incomplete Freund's adjuvant. For Western blotting the 
two antisera pca63 and pcaF6 were diluted 1:5000. The 
specificity of both sera was identical. The monoclonal 
antibody against carp muscle PV, mca 235 [5,20] was 
diluted 1:2000. Alkaline phosphatase conjugated secondary 
antibodies were purchased from Promega (Madison, WI). 
For Western blot analysis proteins were separated on a 
15% PAGE and blotted onto a Nytran membrane. Human 
cerebellum was homogenized in 10 mM Tris (pH 8.0), 1 
mM EDTA, 0.5 mM PMSF, centrifuged at 15 000 × g at 
4°C for 30 min. The cleared supernatant was used for 
Western blot analysis. 
3. Results 
3.1. Purification and electrophoretic characterization of 
recombinant a-parvalbumin and nine mutants 
Each of the mutant proteins contained substitutions in
the Ca2+-binding loops (see Section 2). High expression of 
hPVwt and of the nine mutant proteins was observed in E. 
coli strain BL21(DE3)pLysE by addition of MgC12 to the 
culture medium. As an example, the expression of PVwt is 
illustrated in Fig. 1. A bacterial culture xtract before (Fig. 
1A, lane 1) and after (lane 2) induction with IPTG was 
subjected to SDS-PAGE. After induction, approx. 40% of 
total protein represent parvalbumin. 
Purification of PVwt and nine mutant proteins was 
achieved by a heat step followed by ion exchange chro- 
Table 1 
Biochemical properties of human PVwt and nine mutants 
Protein Isoelectric point Molecular weight 
calculated measured calculated measured 
PVwt 4.84 5.34 5:0.08 
PVEJol v 5.00 5.46 -I- 0.10 
PV~o a 5.02 5.47 5:0.10 
PVE62V 5.00 5.46 5:0.10 
PVD5 IA 5.02 5.49 5:0.10 
PVD90A,EI01V 5.28 5.67 5:0.06 
PVE62V,~101 v 5.26 5.64 5:0.06 
PVo~ JA,D90A 5.29 5.69 5:0.06 
PVD5 IA,E62V 5.28 5.67 5:0.06 
PVD51A,E62V,D90a,E101V 6.54 6.32 + 0.12 
11 927.44 11 927.27 -I- 1.79 
11 897.46 11 898.64 + 1.21 
11 883.43 11 883.64 4- 0.98 
11 897.46 11 897.32 + 0.73 
11 883.43 11 883.19 + 1.43 
11 853.45 11 853.58 -I- 1.00 
11 867.48 11 867.82 5:1.23 
11 839.42 11 839.39 5:0.95 
11 853.45 11 853.80 5:1.41 
11 779.46 11 779.57 + 0.95 
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Fig. 2. Ca 2+ binding to recombinant human PVwv Ca 2+ binding was measured in solutions of 20 to 30 I~M PV by the flow dialysis method at 25°C. 
Mg 2+ concentrations were 0 mM (O, O), 0.5 ~ (*), 2 mM (A), 5 mM (I1), or l0 mM ('0, ~). The curves were calculated with the Kas s constants 
listed in Table 1. Inset: ratio of the intrinsic Ca2+-binding constant in the absence of Mg 2+ over the apparent Ca2+-binding constant in the presence of 
Mg 2+ as a function of [Mg2+]. 
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Fig. 3. Ca 2+ binding to recombinant PV mutants with inactivated CD (A) or EF sites (B), respectively. The PV concentrations were 20 to 30 p,M. Mg 2+ 
concentrations were 0 (open symbols) or 10 mM (closed symbols). (A) O,O,  PVt62v; O,m,  PVDsjA; A ,A  PVD51A.~62.V" (B) 0 ,0 ,  PVEImv; D,m,  
PVD9oA; A, &, PVD90A,EI01v. The curves were calculated with the Kass. constants listed in Table 2. 
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matography. Recombinant proteins were homogeneous as 
judged by Coomassie brilliant blue staining of SDS-PAGE 
(Fig. 1B). Routinely, the yield of purified proteins was 50 
to 70 mg/1 of bacterial culture. 
Analysis of the isoelectric points of each mutant protein 
was carried out under denaturing conditions (summarised 
in Table 1). PVwt was found to be the most acidic protein, 
at pH 5.34, followed by the group of mutants, PVE10~ v, 
PVD90A , PVE62V , and PVDs1A, around pH 5.45, mutants 
PVDq0A,EIO1V , PVE62V,EI01V, PVD51A,Dq0A, and PVD51A,E62 V,
around pH 5.67, and PVD51A,E62V,D90A,E101V, at pH 6.32. 
The measured isoelectric points of the proteins were gener- 
ally more basic when compared to the calculated values. 
The more acidic protein bands shifted by 0.18 pH units 
represent the N-acetylated proteins (see below). 
3.2. ESI-mass spectrometry 
PVD90A,E101V) , where each of the three modifications in the 
EF site leads to a substantial decrease of the affinity of the 
remaining CD site for Ca 2+ as well as for Mg 2+ (Fig. 
3B). Interestingly, the CaE+-affinity depends on how the 
EF site is inactivated (Table 2): the modification in the 
-Z  position of the EF site is more deleterious for the 
affinity than inactivation of the + X position, and inactiva- 
tion of both residues yields a cummulative ffect, l0 mM 
Mg 2+ weakly affects the affinity of the CD site for Ca 2+ 
with calculated g~lg.compet, values of 1.7 to 4.7 × 102 M -1 
(Table 2). As expected, the proteins PVE62V,E101V , 
PVDs1A,D90 A, and PVD51A,E62V,D90A,EI01V with the two sites 
inactivated o not bind Ca 2+ under the experimental con- 
ditions described above. 
3.4. Fluorescence characteristics 
To assure the correct sequence of the PVwt and of the 
nine mutants, their molecular mass was accurately deter- 
mined by ESI-MS. The molecular weights of all proteins 
were found to be in good agreement with the calculated 
values (Table 1). In all mutants a second protein species 
was detected with a mass increase of 42 Da, corresponding 
to N-terminal acetylated protein. 
3.3. Direct binding studies 
Fig. 2 shows the Ca2+-binding isotherms of PVwt in the 
presence of 0, 0.5, 2, 5, and 10 mM Mg 9+ as measured by 
the flow dialysis method. In the absence of Mg 2÷ the 
intrinsic affinity constants of the two sites for Ca 2+ are 
identical and equal to 2.3 X 107 M - l  - i.e., slightly lower 
than that of recombinant rat PV [17]. In increasing Mg 2÷ 
concentrations the isotherms are parallel-shifted to higher 
free Ca 2 ÷ concentrations, suggestive of strict competition 
at both sites. The Ca0. 5 values obey the competition equa- 
tion (see Section 2) with KMg.compet. equal to 4.9 × 103 
M-1 (Fig. 2, inset). 
In comparison with PVwt , Fig. 3 shows the Ca2+-bind - 
ing isotherms of the mutant PVs with a single inactivated 
site in the presence of 0 and 10 mM Mg 2÷. As predicted 
from the sequence, they display only one site for Ca z÷, 
without indications for an additional low-affinity site. The 
PVED (PVE62V , PVD51A , and PVI)51A,62v) mutants display 
Ca 2+- and MgE+-binding properties to the EF site which 
are nearly independent of the way the CD site is inacti- 
vated (Fig. 3A). In the absence of Mg 2+ they display K~a 
values of 2.0 to 2.3 X 10 7 M-~; in the presence of 10 mM 
Mg 2+ the K~a.app" values equal 4.3 to 5.7 X l0 5 M -1. 
Assuming straight competition between Ca 2+ and Mg 2+, 
the K~g.compet. values are 3.4 to 4.6 × 10 3 M - l .  All these 
values are very similar to those of PVwt, suggesting that 
the affinity of the EF site for Ca 2+ and Mg 2+ is not 
influenced by modifications in the CD site. The situation is 
quite different in the PV_EF mutants (PVE101 v, PVD90A, and 
After excitation at 259 nm, metal-free human PWwt 
shows an emission spectrum with a maximum at 283 rim. 
Upon denaturation by 3 M guanidine HC1 the fluorescence 
increases 1.2-fold, whereas upon binding of either Ca 2÷ or 
Mg 2÷ the fluorescence decreases 1.8-fold (Fig. 4). PVDg0A, 
PVE101v,and PVE]01V,D90A mutants show a behavior very 
similar to PVwt. The mutant proteins PVE62V, PVD51A, and 
PVD51A,62V show a denaturation-induced 1.2-fold increase 
in fluorescence and a small 1.1- to 1.2-fold decrease upon 
binding of Ca 2+ or Mg 2+. Finally, PVE62V,E101V , 
PVD51A,D90A, and PVD51A,E62V,D90A,E101V show only a de- 
naturation induced 1.2-fold increase in Phe fluorescence. 
Table 2 
Intrinsic association constants (K') of human PVwt and nine inactivation 
mutants for Ca 2+ and calculated K' for Mg 2+ assuming straight compe- 
tition 
Intrinsic Ca 2+ binding constants (K~a) at varying Mg 2+ concentrations 
PVw t 
Mg 2+ (raM) PVwt g~a/K~a.app" 
0 2.3 X 107 
0.5 1.0x 107 2.3 
2 2.0 x 106 11.5 
5 9.0 × 105 25.6 
10 4.7 × 105 48.9 
PV-cD 
Mg 2+ (raM) PVE62V PVDsIA 
0 2.3 x 107 2.0 X 107 
10 5.0 × 105 5.7 x 105 
KMg.compet. 4.5 X 103 3.4X 103 
PV-EF 
Mg 2+ (mM) PVE101 v PVD90A 
0 4.5x 10 6 7.9×10 6
10 1.6 × 106 1.4 X 106 
K~,lg.compet. 1.8 × 102 4.7 × 102 
=~ K~g.compet. 
=4.9x10 ~
PVD51A,E62V 
2.0x 10 7 
4.3×10 5
4.6x 103 
IaVD90A,EIOIV 
3.6× 106 
1.3 X 106 
1.7 x 102 
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Fig. 4. Fluorescence spectra of PVwt. The protein concentration was 50 p,M. Ca 2+, Mg 2÷ or guanidine hydrochloride were added up to 1 mM, 2 mM, and 
4 M, respectively. The spectra were normalized as described in Section 2. Solid line, Ca 2÷ form; dashed line, Mg 2÷ form; dotted line, metal-free form; 
dashed and dotted line, guanidine hydrochloride-denatured form. 
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Fig. 5. Characterization f antibodies by Western blot analysis. (A) Human cerebellar protein extract (100 Ixg, lanes 1 and 3) and recombinant hPVwt (lane 
2, 2 p,g; lane 4, 100 ng). Proteins were visualized by Coomassie blue (lanes 1 and 2), and detected on Western blot analysis using the pca63 serum (lanes 3 
and 4). Arrow, position of PV (m.wt. 12 kDa). (B) Cross-reactivity of the human antiserum (pca63) with parvalbumins of other species. Top: SDS-PAGE 
stained with Coomassie brilliant blue of muscle PVs from (200 ng each PV) gerbil (lane 1); cat (lane 2); mouse (lane 3); rat (lane 4); PVwt (lane 5). 
Bottom: corresponding Western blot with the pca63 serum. (C) immunoreactivity of the monoclonal anti-carp PV antibody mca235 (top) and of the 
polyclonal anti-human PV serum (pca63; bottom) against human PV~ and the nine mutants (lanes 1-10; order of the samples ee Fig. 1B) by Western blot 
analysis. 100 ng of each protein was applied. 
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3.5. Characterization of the specific polyclonal antibodies 
against human recombinant a-parvalbumin 
The specificity of the antiserum pca63 was tested on 
Western blots against human cerebellum extract (Fig. 5A), 
against parvalbumins from other species (Fig. 5B), and 
against all nine mutant proteins (Fig. 5C). A specific 
immunoreaction for native human brain PV (Fig. 5A, lane 
3) and recombinant human PVwt (lane 4) was observed, 
demonstrating immunological identity. Strong cross-reac- 
tivity of pca63 with muscle a-PV from gerbil, cat, mouse, 
and rat was found and pca63 can therefore be used in these 
species for anatomical, developmental, nd functional stud- 
ies. 
For the monoclonal antibody mca235 directed against 
carp muscle PV a specific epitope was mapped to lysin-54 
located in the CD-loops of carp muscle parvalbumin (iso- 
form with pI = 4.25) [20]. The mca235 was therefore used 
to test the consequences of the different mutations on the 
reactivity toward the antigenic CD-site (Fig. 5C, top). The 
antibody reacted strongly with PVwt (lane 1) and PV_EF 
(lanes 2, 3, 6), whereas a faint or no signal was detected 
with PV_co (lanes 4, 5, 9) and PV_cD_EF (lanes 7, 8, 
10), confirming the previous results. Our polyclonal anti- 
body pca63 shows a similar reactivity (Fig. 5C, bottom), 
reacting stronger with the mutants PV_EF than with the 
PV_co mutants, indicating that pca63 recognizes the same 
epitope as mca235. The additional but decreased reactivity 
against he mutants PV_cD_EF (lanes 7, 8, and 10) indi- 
cates that additional epitopes also in the EF-loop are 
probably recognized. 
These specific and well defined human antibodies can 
now be applied for localization and functional studies in 
human tissues and to monitor pathological changes, e.g., in 
human neurodegenerative disorders. 
4. Discussion 
In the present study nine mutant human parvalbumins 
containing either one or two abortive CaZ+-binding sites in 
their C-terminal tandem domain have been analyzed. The 
highly conserved positions 1 (Asp) and/or 12 (Glu) in the 
12 residue Ca2+-binding loop which provide essential oxy- 
gen ligands for Ca 2+ were replaced by the nonpolar 
residues Ala and Val, respectively. NMR showed that in 
the loops of pike PV these residues exhibit the largest 
changes upon metal binding [21]. The same replacements 
in all three functional loops in yeast calmodulin resulted in 
weak CaE+-binding when position 12 was changed, whereas 
no Ca2+-binding was detectable when positions 1 and 12 
were substituted [22]. Replacements of position 1, D ~ A, 
alone also prevented the binding of Ca 2+ to yeast mutant 
calmodulins, whereas the same replacement for single sites 
in troponin C was not enough to inactivate the mutated site 
[23]. Our data revealed that in human PV the mutation of a 
single one of these critical residues is sufficient o inacti- 
vate cation binding to the site. 
One of the most intriguing observations of our study is 
that, despite the structural symmetry in the 2-sites domain 
of parvalbumin, these two sites do not have the same 
importance within the paired EF-hand domain. In the 
recombinant protein the two sites appear to be equivalent 
with the same affinity for Ca 2+ and the same antagonistic 
effect of Mg2+ on Ca 2+-binding. However, important 
differences are observed when either the N-terminal or the 
C-terminal site is modified so that it can no longer bind 
Ca 2+. When the CD site is inactivated, the remaining EF 
site has still the same high affinity for Ca 2+ as the parent 
PVwt. When the EF site is impaired the CD site binds 
cations with lower affinity. Apparently, in the paired do- 
main the EF site is structurally much more important than 
the CD site and constitutes the stable structural nucleus of 
the paired domain. In addition, we show that the way of 
inactivation can influence the affinity of the remaining 
active site for Ca2+: the inactivation of the CD site is less 
critical than the inactivation of the EF site: the mutation of 
Asp-90 to Ala decreases the affinity of the remaining CD 
site 3.6-fold, of Glu-101 to Val 5.1-fold, and the mutation 
of both residues yields a 6.4-fold decrease. The destabiliza- 
tion of the EF site seems to be gradually changing and 
cummulative. 
The functional importance of parvalbumin as a buffer of 
Ca 2+ and Mg 2+ can now be evaluated by transfection of 
these mutant PVs in living neuronal cells where a model 
can be established that also holds true for human cells. The 
PV_co and PVwt are supposed to be fully saturated with 
Mg 2+ at rest, whereas PV_EF would be mostly in a 
metal-free state. Therefore, upon increase of intracellular 
Ca 2+ levels the former two proteins would first have to 
release their bound Mg 2÷ in order to take up Ca 2+, 
whereas PV_EF could immediately bind Ca 2+. This allows 
to study separately the effect of CaE+/Mg 2+ exchange 
and of Ca 2+ buffering. The mutant PV_cD/_EF can yield 
indications whether the role of parvalbumin is restricted to 
the two above actions or includes also divalent cation-inde- 
pendent functions. 
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